Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Eine Open-Label-Studie zur Bewertung der Sicherheit, Wirksamkeit und Zellkinetik von YTB323 bei schweren, refraktären Autoimmunerkrankungen

14. Oktober 2026 aktualisiert von: Novartis Pharmaceuticals

Eine offene, multizentrische Phase-1/2-Studie zur Bewertung der Sicherheit, Wirksamkeit und Zellkinetik von YTB323 bei Teilnehmern mit schweren, refraktären Autoimmunerkrankungen

The study is intended to assess safety, efficacy and cellular kinetics of YTB323 treatment in participants with severe refractory systemic lupus erythematosus.

Studienübersicht

Status

Abgeschlossen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Tatsächlich)

21

Phase

  • Phase 2
  • Phase 1

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Victoria
      • Clayton, Victoria, Australien, 3168
        • Novartis Investigative Site
      • Mainz, Deutschland, 55131
        • Novartis Investigative Site
    • Baden-Wurttemberg
      • Freiburg im Breisgau, Baden-Wurttemberg, Deutschland, 79106
        • Novartis Investigative Site
      • Paris, Frankreich, 75013
        • Novartis Investigative Site
      • Pessac, Frankreich, 33604
        • Novartis Investigative Site
      • Strasbourg, Frankreich, 67091
        • Novartis Investigative Site
      • Bern, Schweiz, 3010
        • Novartis Investigative Site
      • Lausanne, Schweiz, 1011
        • Novartis Investigative Site
      • Barcelona, Spanien, 08035
        • Novartis Investigative Site
      • Madrid, Spanien, 28009
        • Novartis Investigative Site

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 65 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Signed informed consent
  • Adequate renal, hepatic, cardiac, hematological and pulmonary function
  • Men and women with SLE, aged ≥18 years and ≤65 years at screening, fulfilling the 2019 European League Against Rheumatism EULAR/ACR classification criteria for SLE.
  • Patient must be positive for at least one of the following autoantibodies at screening: antinuclear antibodies (ANA) at a titer of ≥1:80, or anti dsDNA (above the ULN); or anti-Sm (above the ULN)
  • Active (severe) disease as defined by SLEDAI-2K ≥ 8 (not including the SLEDAI-2K domains of lupus headache, cerebrovascular accident, organic brain syndrome) and at least one of the following significant SLE related organ involvements:
  • Renal
  • At least moderate or severe peri/myocarditis
  • At least moderate or severe pleuritis or other lung involvement
  • Vasculitis
  • Failure to respond to two or more standard immunosuppressive therapies (including one of mycophenolate or cyclophosphamide), unless contraindicated or having experienced documented adverse events or intolerance related to such immunosuppressive drugs not allowing their further use, in combination with glucocorticoids and failure to respond to at least one biological agent (unless contraindicated, the patient deemed ineligible by the Investigator or not available in a country).

Exclusion Criteria:

  • Clinically significant active, opportunistic, chronic or recurrent infection confirmed by clinical evidence, imaging, or positive laboratory tests (e.g., blood cultures, PCR for DNA/RNA, such as COVID-19 etc.) one month prior to or during screening. Patients who have had at least one severe infection that required prolonged hospitalization in the intensive care setting within 5 years prior to screening and/or at least one severe infection that required prolonged hospitalization within one year prior to screening.
  • Uncontrolled diabetes mellitus, lung diseases or any other illness that are not related to SLE that in the opinion of the Investigator would jeopardize the ability of the patient to tolerate lymphodepletion and CD19 CAR-T cell therapy
  • Prior history of malignancy except for localized basal cell or squamous skin cancer. Other malignancies for which the patient is judged to be cured by local surgical therapy, such as head and neck cancer, or stage I breast cancer will be considered on an individual basis
  • Any patients requiring medications prohibited by the protocol
  • Any psychiatric condition or disability making compliance with treatment or informed consent impossible
  • Prior treatment with anti-CD19 therapy, adoptive T cell therapy or any prior gene therapy product (e.g. CAR-T cell therapy)
  • History of bone marrow/hematopoietic stem cell or solid organ transplantation
  • Female participants who are pregnant or breastfeeding, or intending to conceive during the course of the study
  • Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using a highly effective method of contraception starting from the time of enrollment to at least 12 months after the YTB323 infusion (or longer if required as per local regulations) and until CAR-T cells are no longer present by qPCR on two consecutive tests
  • Sexually active males unwilling to use a condom during intercourse from the time enrollment for at least 12 months after the YTB323 infusion and until CAR-T cells are no longer present by qPCR on two consecutive tests
  • Any acute, severe lupus related flare during screening that needs immediate treatment and/or makes the immunosuppressive washout impossible; thus, makes the patient ineligible for CD19 CAR-T therapy as judged by the Investigator, such as acute central nervous system (CNS) lupus (e.g. psychosis, epilepsy) or catastrophic antiphospholipid syndrome
  • Significant, likely irreversible organ damage related to SLE, e.g. end stage renal disease, that in the opinion of the Investigator renders CD19 CAR-T cell therapy would be unlikely to benefit the patient
  • B cell aplasia

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: N / A
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: YTB323

Single infusion of YTB323

Single infusion of YTB323

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Number of participants with AEs and SAEs
Zeitfenster: Day 1 to 2 years

Long term safety follow up

Day 1 to 2 years

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
CAR transgene levels by quantitative polymerase chain reaction (qPCR) in blood (Maximum observed blood concentration Cmax)
Zeitfenster: Pre-dose, up to 2 years

Blood samples will be collected to assess cellular kinetics.

Pre-dose, up to 2 years
CAR transgene levels by quantitative polymerase chain reaction (qPCR) in blood (Area under plasma concentration -time AUC)
Zeitfenster: Pre-dose, up to 2 years

Blood samples will be collected to assess cellular kinetics.

Pre-dose, up to 2 years
CAR transgene levels by quantitative polymerase chain reaction (qPCR) in blood (Time to reach maximum concentration Tmax)
Zeitfenster: Pre-dose, up to 2 years

Blood samples will be collected to assess cellular kinetics.

Pre-dose, up to 2 years
CAR transgene levels by quantitative polymerase chain reaction (qPCR) in blood (Terminal elimination half-life T1/2)
Zeitfenster: Pre-dose, up to 2 years

Blood samples will be collected to assess cellular kinetics.

Pre-dose, up to 2 years
CAR transgene levels by quantitative polymerase chain reaction (qPCR) in blood (Last measurable concentration Clast)
Zeitfenster: Pre-dose, up to 2 years

Blood samples will be collected to assess cellular kinetics.

Pre-dose, up to 2 years
CAR transgene levels by quantitative polymerase chain reaction (qPCR) in blood (Time to reach last measurable concentration Tlast)
Zeitfenster: Pre-dose, up to 2 years

Blood samples will be collected to assess cellular kinetics.

Pre-dose, up to 2 years
Number of patients with anti-drug antibodies
Zeitfenster: Pre-dose, up to 2 years

Blood samples will be collected to measure anti-drug antibodies against YTB323.

Pre-dose, up to 2 years
Level of T cell activation by YTB323
Zeitfenster: Pre-dose, up to 2 years

Blood samples will be collected to measure the level of T cell activation by YTB323.

Pre-dose, up to 2 years
Number of patients infused with planned target dose
Zeitfenster: Day 1

Feasibility of the manufacturing process in autoimmune disorders.

Day 1
Change from pre-dose up to 2 years in the Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) score
Zeitfenster: Pre-dose, up to 2 years

SLEDAI-2K scores are between 0 and 105, a higher score represents a higher disease activity.

Pre-dose, up to 2 years
Change from pre-dose up to 2 years in Physician's global assessment (PGA)
Zeitfenster: Pre-dose, up to 2 years

The Physician's Global assessment is a visual analog scale from 0 to 3, 0 represents no activity and 3 represents severe disease activity.

Pre-dose, up to 2 years
Change from pre-dose up to 2 years in Lupus Low Disease Activity State (LLDAS)
Zeitfenster: Pre-dose, up to 2 years

LLDAS is a composite measure based on: SLEDAI-2K ≤ 4, with no activity in major organ system (renal, central nervous system, cardiopulmonary, vasculitis, and fever) and no hemolytic anemia or gastrointestinal activity, current, no new lupus disease activity compared with the previous assessment, prednisone (or its equivalent) dose ≤ 7.5 mg/day, PGA (scale 0-3) ≤ 1, well tolerated standard maintenance doses of immunosuppressive lupus therapy.

Pre-dose, up to 2 years
Remission rate
Zeitfenster: Up to 2 years

Remission as specified by Definitions Of Remission In Systemic Lupus Erythematosus (DORIS) criteria: Clinical SLEDAI=0, PGA<0.5 (0-3) irrespective of serology.

The patient may be on antimalarials, low-dose glucocorticoids (prednisolone ≤5 mg/day), and/or stable immunosuppressive therapy including biologics.

Up to 2 years
Change from pre-dose up to 2 years in Urinary protein creatinine ratio (UPCR)
Zeitfenster: Pre-dose, up to 2 years

Change in the value of UPCR.

Pre-dose, up to 2 years
Incidence of Complete renal response (CRR)
Zeitfenster: Up to 2 years

Number of participants who achieved CRR.

Up to 2 years

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Studienleiter: Novartis Pharmaceuticals, Novartis Pharmaceutical

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

28. Februar 2023

Primärer Abschluss (Tatsächlich)

24. September 2026

Studienabschluss (Tatsächlich)

24. September 2026

Studienanmeldedaten

Zuerst eingereicht

27. Februar 2023

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

22. März 2023

Zuerst gepostet (Tatsächlich)

4. April 2023

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

15. Oktober 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

14. Oktober 2026

Zuletzt verifiziert

1. Oktober 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren